MarketLens

ProMIS Neurosciences' PMN310: Differentiated Safety Profile Unlocks Alzheimer's Upside

1 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Does Director Kirwin's Recent Insider Buy Signal for ProMIS Neurosciences

4 months ago

What is Driving Jupiter Neurosciences' Recent Stock Volatility

3 months ago

AMD's AI Inference Bet: A Premium Price for a Differentiated Growth Story

2 months ago

What's Driving 3M and Bain Capital's Big Bet on Fire & Safety

5 months ago

LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease

Eisai's LEQEMBI IQLIK autoinjector is now available in the U.S. for early Alzheimer's disease, enabling at-home initiation and maintenance dosing. It is the first anti-amyloid treatment worldwide to o...

BIIB

Stock News•3 weeks ago

ClearPoint Neuro: Regulatory Momentum Strengthens The Long-Term Investment Case

ClearPoint Neuro's Q2 results were weak, with drug delivery disposables lagging and preclinical service delays cutting 2026 expectations. Regulatory clarity now makes a revenue inflection likely in 20...

CLPT

Stock News•1 months ago

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial

ProMIS Neurosciences' PMN310 showed no ARIA-E across all genotypes in a Phase 1b interim analysis, with early biomarker movement suggesting target engagement. 12-month topline results are expected in ...

PMN

Stock News•1 months ago

INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study

INmune Bio's XPro1595 prevented brain-injury-induced Alzheimer's pathology, memory loss, and pain in a peer-reviewed preclinical study, pointing to soluble TNF as a key biological link.

INMB